Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Apoptosis Regulation Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for XAF1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | XAF1 Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. E. coli or Eukaryotic expression systems optimized for zinc-finger stability. |
View XAF1 Products |
| Gene Delivery | XAF1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines to study apoptosis restoration. |
View XAF1 Products |
| Benchmark Ab | Anti-XAF1 Antibody Recombinant positive control for Western Blot, IHC, and IP validation. |
View XAF1 Products |
| Validator | XAF1 siRNA Set For knockdown verification in functional rescue assays. |
View XAF1 Products |
| Related Target A | XIAP (X-linked Inhibitor of Apoptosis) Direct binding partner of XAF1; XAF1 antagonizes XIAP-mediated caspase inhibition. |
View XIAP Products |
| Related Target B | TP53 (Tumor Protein p53) XAF1 interacts with p53 to create a positive feedback loop, enhancing p53-mediated apoptosis. |
View TP53 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Zinc-Finger Folding & Conformational Stability | Recombinant XAF1 proteins expressed with optimized zinc ion supplementation to ensure native structural conformation. |
| Protein-Protein Interaction (PPI) Screening | High-purity XAF1 and XIAP partner proteins available with distinct tags (GST/His/Fc) for robust AlphaLISA/HTRF assay development. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies and positive control expression vectors included |
| False Positives | Validated siRNA sets included for target specificity and gene knockdown validation |
Live XAF1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
"The race for XAF1 therapeutics is intensifying, with major players shifting focus from traditional gene therapies to targeted small-molecule protein-protein interaction (PPI) disruptors and mRNA-based restoration. As first-generation apoptosis-sensitizing therapies reach the clinic, the next wave of R&D is targeting the reactivation of endogenous tumor suppressors like XAF1 to overcome chemotherapeutic resistance."
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Gene Therapy / Oncolytic Virus | Academic Medical Centers, Biotech Startups | Gastrointestinal Cancers, Melanoma, Glioma | Overexpression Validation (Need high-titer Lentivirus & validated siRNA controls) |
| Small Molecule (PPI Inhibitors) | Pharmaceutical Developers | Refractory Solid Tumors, Hematological Malignancies | Binding Affinity/Disruption Assay (Need high-purity XAF1 & XIAP recombinant proteins) |
| mRNA Therapeutics | RNA Therapeutics Innovators | Advanced Epithelial Ovarian Cancer, Colon Cancer | Expression & Intracellular Localization (Need sequence-verified antibodies for Western Blot/IHC) |